logo
logo
Profound Medical Corp.

Profound Medical Corp.

NASDAQ•PROF
CEO: Dr. Arun Swarup Menawat MBA, Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2019-10-29
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
連絡先情報
2400 Skymark Avenue, Unit 6, Mississauga, ON, L4W 5K5, Canada
647-476-1350
www.profoundmedical.com
時価総額
$199.33M
PER (TTM)
-5.0
29.8
配当利回り
--
52週高値
$8.95
52週安値
$3.76
52週レンジ
55%
順位60Top 89.2%
2.1
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$5.23M+36.57%
直近4四半期の推移

EPS

$0.26-168.42%
直近4四半期の推移

フリーCF

-$9.48M+38.88%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Nine-month revenue reached $10.12M, increasing 56% driven by US capital sales and recurring revenue growth.
Gross Profit Surges Three-month Gross Profit $3.93M, surging 120%; Gross Margin improved substantially to 74% from 63%.
Capital Sales Driver Nine-month Capital Equipment revenue $2.69M, a major driver, compared to $952K in the prior nine months.
R&D Investment Ramps Nine-month R&D expenses reached $16.32M, increasing 33% due to CAPTAIN trial enrollment and headcount growth.

リスク要因

Liquidity Concerns Exist Cash balance $24.83M insufficient for next twelve months operations, raising substantial going concern uncertainty.
Debt Covenant Breach Risk Projected violation of CIBC Credit Agreement liquidity covenant by June 30, 2026, risking immediate debt acceleration.
Operating Costs Rising Nine-month operating expenses climbed 43% to $41.29M, driven by R&D and SG&A expansion costs.
Net Loss Widening Nine-month Net Loss attributed to shareholders $34.40M, representing a 50% increase in period loss.

見通し

Financing Strategy Underway Management actively pursuing equity, debt, or strategic alliances to secure funding for operations beyond next year.
Internal Control Remediation Internal control remediation for revenue recognition ongoing; expected completion of management's plan during fiscal year 2025.
Product Adoption Focus Continued substantial investment in R&D to support reimbursement efforts and further product development initiatives.
Future Compliance Dependent Future CIBC covenant compliance hinges on achieving specific revenue targets, EBITDA levels, and unrestricted cash balances.

同業比較

売上高 (TTM)

Neuronetics, Inc.STIM
$129.87M
+78.6%
Owlet, Inc.OWLT
$99.66M
+26.8%
Sight Sciences, Inc.SGHT
$76.05M
-4.4%

粗利益率 (最新四半期)

MaxCyte, Inc.MXCT
92.4%
+16.1pp
Sight Sciences, Inc.SGHT
86.4%
+2.5pp
TriSalus Life Sciences, Inc.TLSI
83.5%
-2.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
FBRX$402.24M-11.0-75.6%0.0%
CATX$349.39M-3.3-39.1%1.1%
ARMP$296.72M-6.370.3%198.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.6%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月5日
|
EPS:-$0.28
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月13日|
    売上高: $5.23M+36.6%
    |
    EPS: $0.26-168.4%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月14日|
    売上高: $2.21M-1.0%
    |
    EPS: $-0.52+85.7%
    予想を下回る

  • Form 40-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月7日|
    売上高: $7.20M+7.8%
    |
    EPS: $-1.35+2.2%
    予想を下回る

  • Form 40-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月7日|
    売上高: $6.68M-2.8%
    |
    EPS: $-1.38+8.0%
    予想通り

  • Form 40-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月3日|
    売上高: $6.87M-5.9%
    |
    EPS: $-1.50-20.0%
    予想通り

  • Form 40-F - FY 2020

    会計期末: 2020年12月31日|提出日: 2021年3月2日|
    売上高: $7.30M+75.0%
    |
    EPS: $-1.25+10.1%
    予想を上回る